Panitumumab in combination with preoperative radiation therapy in patients with locally advanced RAS wild-type rectal cancer: results of the multicenter explorative single-arm phase 2 study NEORIT
Purpose: Studies investigating combinations of anti-epidermal growth factor receptor monoclonal antibodies such as panitumumab or cetuximab with standard chemoradiation therapy protocols in rectal cancer have yielded disappointing results. Because of the supposed negative interaction of epidermal gr...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
28 Juni 2017
|
| In: |
International journal of radiation oncology, biology, physics
Year: 2017, Jahrgang: 99, Heft: 4, Pages: 867-875 |
| ISSN: | 1879-355X |
| DOI: | 10.1016/j.ijrobp.2017.06.2460 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ijrobp.2017.06.2460 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0360301617335435 
|
| Verfasserangaben: | Kirsten Merx, MD, Uwe M. Martens, MD, Melanie Kripp, MD, Thomas Hoehler, MD, Michael Geissler, MD, Timo Gaiser, MD, Sabine Mai, MD, Peter Kienle, MD, Sebastian Belle, MD, Christoph Plöger, MD, Udo Hieber, MD, Frederik Wenz, MD, Stefan Post, MD, and Ralf D. Hofheinz, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577256662 | ||
| 003 | DE-627 | ||
| 005 | 20240316100450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180704s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijrobp.2017.06.2460 |2 doi | |
| 035 | |a (DE-627)1577256662 | ||
| 035 | |a (DE-576)507256662 | ||
| 035 | |a (DE-599)BSZ507256662 | ||
| 035 | |a (OCoLC)1341013259 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Merx, Kirsten |d 1970- |e VerfasserIn |0 (DE-588)122413091 |0 (DE-627)70589892X |0 (DE-576)293258910 |4 aut | |
| 245 | 1 | 0 | |a Panitumumab in combination with preoperative radiation therapy in patients with locally advanced RAS wild-type rectal cancer |b results of the multicenter explorative single-arm phase 2 study NEORIT |c Kirsten Merx, MD, Uwe M. Martens, MD, Melanie Kripp, MD, Thomas Hoehler, MD, Michael Geissler, MD, Timo Gaiser, MD, Sabine Mai, MD, Peter Kienle, MD, Sebastian Belle, MD, Christoph Plöger, MD, Udo Hieber, MD, Frederik Wenz, MD, Stefan Post, MD, and Ralf D. Hofheinz, MD |
| 264 | 1 | |c 28 Juni 2017 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 28 June 2017 | ||
| 500 | |a Gesehen am 04.07.2018 | ||
| 520 | |a Purpose: Studies investigating combinations of anti-epidermal growth factor receptor monoclonal antibodies such as panitumumab or cetuximab with standard chemoradiation therapy protocols in rectal cancer have yielded disappointing results. Because of the supposed negative interaction of epidermal growth factor receptor inhibition and chemoradiation therapy, we conducted a phase 2 study using single-agent panitumumab in combination with radiation therapy in patients with RAS wild-type locally advanced rectal cancer. Methods and Materials: Patients with RAS wild-type locally advanced (clinical stage II or III) rectal cancer localized 0 to 12 cm from the anus were eligible for study participation. The primary objective of the study was to determine pathologic complete response (pCR). Secondary objectives comprised assessing the safety, surgical morbidity, clinical response, tumor downstaging, and tumor regression grading according to Dworak. Results: A total of 54 patients with a median age of 58 years were treated. In 3.7% of patients, pCR was achieved. Downstaging of the primary tumor or lymph nodes was seen in 65% of patients. No grade ≥2 hematologic toxicity was seen. The most common grade ≥3 nonhematologic toxicities were skin toxicity (24%) and diarrhea (10%). Conclusions: Panitumumab in combination with radiation therapy as neoadjuvant treatment for locally advanced rectal cancer showed a favorable toxicity profile but failed to meet the predefined pCR rate to justify further clinical trials. | ||
| 700 | 1 | |a Kripp, Melanie |d 1978- |e VerfasserIn |0 (DE-588)133370925 |0 (DE-627)544030133 |0 (DE-576)299802183 |4 aut | |
| 700 | 1 | |a Gaiser, Timo |d 1975- |e VerfasserIn |0 (DE-588)1030402280 |0 (DE-627)735221685 |0 (DE-576)378226533 |4 aut | |
| 700 | 1 | |a Mai, Sabine |d 1964- |e VerfasserIn |0 (DE-588)1048197883 |0 (DE-627)779968042 |0 (DE-576)402013913 |4 aut | |
| 700 | 1 | |a Kienle, Peter |d 1966- |e VerfasserIn |0 (DE-588)1030310262 |0 (DE-627)735023476 |0 (DE-576)378115898 |4 aut | |
| 700 | 1 | |a Belle, Sebastian |d 1976- |e VerfasserIn |0 (DE-588)134303415 |0 (DE-627)69224140X |0 (DE-576)278646646 |4 aut | |
| 700 | 1 | |a Wenz, Frederik |d 1966- |e VerfasserIn |0 (DE-588)113310390 |0 (DE-627)663837766 |0 (DE-576)346656281 |4 aut | |
| 700 | 1 | |a Post, Stefan |d 1954- |e VerfasserIn |0 (DE-588)1026227518 |0 (DE-627)726294667 |0 (DE-576)371524598 |4 aut | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of radiation oncology, biology, physics |d Amsterdam [u.a.] : Elsevier Science, 1975 |g 99(2017), 4, Seite 867-875 |h Online-Ressource |w (DE-627)306659662 |w (DE-600)1500486-7 |w (DE-576)081986319 |x 1879-355X |7 nnas |a Panitumumab in combination with preoperative radiation therapy in patients with locally advanced RAS wild-type rectal cancer results of the multicenter explorative single-arm phase 2 study NEORIT |
| 773 | 1 | 8 | |g volume:99 |g year:2017 |g number:4 |g pages:867-875 |g extent:9 |a Panitumumab in combination with preoperative radiation therapy in patients with locally advanced RAS wild-type rectal cancer results of the multicenter explorative single-arm phase 2 study NEORIT |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijrobp.2017.06.2460 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0360301617335435 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180704 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 65500 |e 60000PH121917517 |e 65500PH121917517 |k 0/60000/ |k 1/60000/65500/ |p 14 |y j | ||
| 998 | |g 1026227518 |a Post, Stefan |m 1026227518:Post, Stefan |d 60000 |d 61800 |e 60000PP1026227518 |e 61800PP1026227518 |k 0/60000/ |k 1/60000/61800/ |p 13 | ||
| 998 | |g 113310390 |a Wenz, Frederik |m 113310390:Wenz, Frederik |d 60000 |d 63000 |e 60000PW113310390 |e 63000PW113310390 |k 0/60000/ |k 1/60000/63000/ |p 12 | ||
| 998 | |g 134303415 |a Belle, Sebastian |m 134303415:Belle, Sebastian |d 60000 |d 61100 |e 60000PB134303415 |e 61100PB134303415 |k 0/60000/ |k 1/60000/61100/ |p 9 | ||
| 998 | |g 1030310262 |a Kienle, Peter |m 1030310262:Kienle, Peter |d 60000 |d 50000 |e 60000PK1030310262 |e 50000PK1030310262 |k 0/60000/ |k 0/50000/ |p 8 | ||
| 998 | |g 1048197883 |a Mai, Sabine |m 1048197883:Mai, Sabine |d 60000 |d 63000 |e 60000PM1048197883 |e 63000PM1048197883 |k 0/60000/ |k 1/60000/63000/ |p 7 | ||
| 998 | |g 1030402280 |a Gaiser, Timo |m 1030402280:Gaiser, Timo |d 60000 |d 63400 |e 60000PG1030402280 |e 63400PG1030402280 |k 0/60000/ |k 1/60000/63400/ |p 6 | ||
| 998 | |g 133370925 |a Kripp, Melanie |m 133370925:Kripp, Melanie |d 60000 |d 61200 |e 60000PK133370925 |e 61200PK133370925 |k 0/60000/ |k 1/60000/61200/ |p 3 | ||
| 998 | |g 122413091 |a Merx, Kirsten |m 122413091:Merx, Kirsten |d 60000 |d 61200 |e 60000PM122413091 |e 61200PM122413091 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1577256662 |e 3016076896 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Kirsten Merx, MD, Uwe M. Martens, MD, Melanie Kripp, MD, Thomas Hoehler, MD, Michael Geissler, MD, Timo Gaiser, MD, Sabine Mai, MD, Peter Kienle, MD, Sebastian Belle, MD, Christoph Plöger, MD, Udo Hieber, MD, Frederik Wenz, MD, Stefan Post, MD, and Ralf D. Hofheinz, MD"]},"person":[{"family":"Merx","role":"aut","given":"Kirsten","display":"Merx, Kirsten"},{"family":"Kripp","given":"Melanie","role":"aut","display":"Kripp, Melanie"},{"display":"Gaiser, Timo","given":"Timo","role":"aut","family":"Gaiser"},{"family":"Mai","role":"aut","given":"Sabine","display":"Mai, Sabine"},{"given":"Peter","role":"aut","display":"Kienle, Peter","family":"Kienle"},{"display":"Belle, Sebastian","role":"aut","given":"Sebastian","family":"Belle"},{"family":"Wenz","display":"Wenz, Frederik","role":"aut","given":"Frederik"},{"display":"Post, Stefan","role":"aut","given":"Stefan","family":"Post"},{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","role":"aut","given":"Ralf-Dieter"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"28 Juni 2017","dateIssuedKey":"2017"}],"recId":"1577256662","physDesc":[{"extent":"9 S."}],"id":{"doi":["10.1016/j.ijrobp.2017.06.2460"],"eki":["1577256662"]},"relHost":[{"part":{"text":"99(2017), 4, Seite 867-875","year":"2017","volume":"99","extent":"9","pages":"867-875","issue":"4"},"language":["eng"],"title":[{"title":"International journal of radiation oncology, biology, physics","subtitle":"the official journal of the American Society for Therapeutic Radiology and Oncology","title_sort":"International journal of radiation oncology, biology, physics"}],"pubHistory":["1.1975/76 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"306659662","origin":[{"publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier Science","dateIssuedDisp":"1975-","dateIssuedKey":"1975"}],"note":["Gesehen am 15.01.20","Ungezählte Beil.: Supplement"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Panitumumab in combination with preoperative radiation therapy in patients with locally advanced RAS wild-type rectal cancer results of the multicenter explorative single-arm phase 2 study NEORITInternational journal of radiation oncology, biology, physics","id":{"issn":["1879-355X"],"zdb":["1500486-7"],"eki":["306659662"]}}],"note":["Available online 28 June 2017","Gesehen am 04.07.2018"],"title":[{"title_sort":"Panitumumab in combination with preoperative radiation therapy in patients with locally advanced RAS wild-type rectal cancer","title":"Panitumumab in combination with preoperative radiation therapy in patients with locally advanced RAS wild-type rectal cancer","subtitle":"results of the multicenter explorative single-arm phase 2 study NEORIT"}],"language":["eng"]} | ||
| SRT | |a MERXKIRSTEPANITUMUMA2820 | ||